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Abstract
Objective:  To examine the variation of cadmium (Cd), zinc (Zn) and mitochondrial DNA (mtDNA) copy
number in prostate cancer (PCa) patients and their age match controls and correlations with clinicopatho-
logical parameters.
Subjects  and  methods: This study was conducted between January 2012 and January 2015. Blood Cd andRT-PCR;
Zn level was measured by inductively coupled plasma spectrophotometer. The variation of mitochondrial
sured by real-time PCR. We scrutinized the correlation of Cd, Zn and mtDNA
eters like prostate specific antigen (PSA) and [Gleason] score.
/L ±  SD) was significantly higher (3.89 ±  1.49) while Zn level was
ents comparison to control patients (2.92 ±  1.23; 116 ±  19.1). A wideGleason score copy number in blood was mea
with clinicopathological param
Results:  Mean Cd level (g
low (85 ±  10.4) in PCa patiPlease cite this article in press as: Abhishek A, et al. To study the relationship between cadmium, zinc and mtDNA copy number in North
Indian patients suffering from prostate cancer: A case control study. Afr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2016.05.011
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distribution of variance and higher mtDNA copy numbers were found in PCa patients [Range (fold
difference) 1968–39,245 (17.4)] as compared to controls [10,178–332,243.9], (p  value: 0.036). Clinico-
pathological analysis showed that Cd, Zn and mtDNA DNA copy numbers were significantly associated
with increased [Gleason] score but not with serum PSA level (Zn: r  = −0.68; Cd: r  = 0.64; mtDNA: r  = 0.84)
(p < 0.05).
Conclusion:  Cd, Zn and mtDNA copy number significantly correlate with [Gleason] score which suggests
that the former may serve as marker for therapeutic guidance.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rostate cancer (PCa) is frequently being diagnosed in elderly men,
ith multi-factorial etiology. Cadmium (Cd) is characterized by
arious degrees of toxicity to non-target species, including human
eings. It is also classified as human carcinogen, based on epidemio-
ogical and rodent experiments [1,2]. Cd enters the cells by utilizing
ransport pathways evolved for essential metals. Cd follows a Trojan
orse strategy by molecular mimicry and interferes with essential
etals homeostasis. In prostatic cells, cadmium toxicity has been
losely related to zinc homeostasis. Zinc (Zn) is a key regulatory fac-
or in the intermediary metabolism of prostate cells and any changes
n Zn homeostasis contributes to the development and progression
f PCa [3].
everal mechanisms of metal carcinogenesis have been proposed,
he most important appears to be oxidative stress which responsi-
le for DNA damage [4]. Mitochondria implemented intracellular
argets for various metals including Cd are central to the forma-
ion of reactive oxygen species (ROS). Mitochondrial dysfunction is
losely related to mitochondrial DNA (mtDNA) copy number which
s expressed as increase or decrease of mtDNA copy number. In
ddition, human mtDNA lacks protective histones, introns, mtDNA
roofreading and has limited DNA repair capacity [5]. These fea-
ures make it highly susceptible to ROS and other types of damage
hat could lead to sequence mutations or copy number alterations
n mtDNA. Normally the amount of mtDNA remains relatively sta-
le in order to maintain the energy demand and protect its standard
hysiological condition [6]. Fluctuation in mtDNA copy number
ay affect mitochondrial dysfunction, and has been observed in
arious types of malignancy including PCa [7].
ince Cd and Zn play a vital role in normal and cancerous tissues, we
ypothesize that Cd and Zn influence distribution pattern of mtDNA
opy number. Hence, present study focuses on investigation of Cd,
n and mtDNA from blood of PCa patients and their respective
ontrols. We also examined the association of Cd, Zn and mtDNA
opy number with other markers of prostate cancer such as Gleason
core and serum PSA.
ubjects  and  methodsPlease cite this article in press as: Abhishek A, et al. To study the relatio
Indian patients suffering from prostate cancer: A case control study. A
thical  consideration  and  sample  collection
his study was approved by the Research Ethics Committee (775/R-
ell-12) of King George’s Medical University (Lucknow, India).
c
9
m
Damples were collected after obtaining a written informed consent
rom each subject (cases and controls) prior to their inclusion in
his study. A total of 102 patients with histopathologically con-
rmed prostate cancer cases were recruited between January 2012
o January 2015 at Department of Urology, King George’s Medical
niversity, Lucknow. Benign prostatic hyperplasia (BPH) (n  = 107)
atients were recruited as control during the same time frame in
his study and were defined as men with no evidence of PCa or
ny other malignancy. All were interviewed to collect information
ncluding age, alcohol consumption, smoking/tobacco chewing, and
amily history of cancer. After proper consent, 5 ml venous blood
as collected and stored as per protocol.
etal  analysis
lood Cd and Zn were measured using inductively coupled plasma
pectrometer (Thermo Electron; Model IRIS Intrepid II XDL, USA)
n the acid digested samples (nitric acid:perchloric acid, v/v). One
l blood samples were digested with digestion mixture (nitric
cid:perchloric acid, v/v) according to the method of Siddiqui et al.
8].
NA  extraction  and  analyses  of  mtDNA  copy  number  using
eal-time  quantitative  PCR
he genomic DNA is isolated by conventional phenol chloro-
orm extraction method followed by ethanol precipitation and
e-suspended in Tris-EDTA buffer and stored at −20 ◦C for further
se. mtDNA copy number was determined as described previ-
usly [9]. In brief, ND1  region (108 bp) of mtDNA was amplified
y using forward primer: 5′-TGACCCTTGGCCATAATATGATTT-
′; reverse primer: 5′-TTCGATGTTGAAGCCTGAGACTAG-3′
Invitrogen, Cat#4304970) and Dual-labeled probe (6FAM-
′
-AGACCAACCGAACCCCCTTCGACC-3′-Taq-Man TAMRA)
Invitrogen Cat#450025). Primers for -globin gene (106 bp) was
sed as described previously and the sequences are as follows:
orward primer: 5′-GTGAAGGCTCATGGCAAGAAAG-3′ and
everse primer: 5′-TGTCACAGTGCAGCTCACTCAGT-3′. Reac-
ions were run in duplicate manner on ABIPRISM 7700 Sequence
etector (Applied [Biosystem], Forest City, USA). The reac-
ion consisted of: 1x Premix Ex Taq (TaKaRa), 2.5 l DNA
ample, 200 nM each primers, 250 nM dual-labeled probe. Thenship between cadmium, zinc and mtDNA copy number in North
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2016.05.011
ycling condition was 95 ◦C for 10 s, followed by 40 cycles at
5 ◦C for 5 s and 60 ◦C for 30 s. Recombinant plasmid containing
tDNA fragment in NDI  gene coding region was used as standard
NA.
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Table  1  Principal clinicopathological characteristics in PCa and BPH controls patients.
Variables Prostate cancer (n = 102) Control (n = 107) OR (95% CI) p value
Age (%)
≤70 72 76 0.86 (0.46–1.6) 0.63
>70 30 31
Smoking History/tobacco chewing
No 11 33 3.68 (1.7–7.7)
Yes 91 74 0.001*
Alcohol consumption
No 16 26 1.72 (0.86–3.44)
Yes 86 81 0.12
Family history (%)
No 97 –
Yes 5 –
Dietary habit
Vegetarian 67 79 0.67 (0.37–1.22)
Non-vegetarian 35 28 0.198
Occupation
Farmer 82 60 3.21 (1.7–5.9)
Others 20 47 0.002*
PSA (ng/ml)
<4 5 82
>4–10 20 15
>10–20 39 7
>20 38 2 0.001*
Figure  1  Bar diagram indicating the mean ±  SD values of cadmium
in PCa and BPH controls. Line and asterisks indicate statistically sig-
nificant difference (**p < 0.05).
Table  2  Correlation of cadmium and zinc with serum PSA and
Gleason score in PCa and BPH Control.
PCa Control
R p R p
Cd with serum PSA 0.00 0.969 −0.16 0.105
Zn with serum PSA −0.10 0.292 0.12 0.232
*OR: odds ratio; CI: confidence interval; p: probability.
* p < 0.05.
Statistical  analysis
Odds ratio (OR), confidence interval 95% (CI 95%) and Chi
square test was calculated for demographic variable. Spearman
rank correlation analysis was applied in studying the relationship
between metals, mtDNA and clinicopathological parameters. One
way ANOVA was perform for Cd and Zn for multiple comparisons
with different Gleason score in PCa patients. One way analysis was
performed for mtDNA copy number in the different groups of PSA
and Gleason score. All statistical calculations were carried out using
the statistical package for the social science, version 16.0 (SPSS Inc.
Chicago, IL, USA) and 3D curve were plotted between the mtDNA
copy number against Cd and Zn using software Statistica (Statistica
AGE, version 12.0, USA). Difference were considered significant
when p  < 0.05.
Results
The patient’s demographic information is demonstrated in Table 1.
There were no statistically significant differences between the
PCa patients and BPH controls in terms of age (OR, 95% CI:
0.86 (0.46–1.6), p: 0.63); alcohol consumption (OR, 95% CI:
1.72 (0.86–3.44), p: 0.12) and dietary habit (OR, 95% CI: 0.67
(0.37–1.22), p: 0.19). A significant difference was observed in addic-
tion habits such as smoking/tobacco chewing (p: 0.001) and clinical
parameter of serum PSA (p: 0.001) in PCa compare to BPH control.
The Cd level (mean ±  SD g/L) in BPH control was 2.92 ±  1.23
whereas in PCa group was 3.89 ±  1.49 (Fig. 1). Meanwhile Zn level
was low (85 ±  10.4) in PCa as compared to BPH (116 ±  19.1) andPlease cite this article in press as: Abhishek A, et al. To study the relationship between cadmium, zinc and mtDNA copy number in North
Indian patients suffering from prostate cancer: A case control study. Afr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2016.05.011
the differences was found statistically significant (p: 0.001) (Fig. 2).
No correlation was found between metals (Cd and Zn) and serum
PSA in case of PCa and BPH (Table 2). Low mean value of Cd
was found in low and intermediate risk patients (Gleason score: 5,
Cd with Gleason score 0.64 0.001
Zn with Gleason score −0.68 0.001*
R: correlation; p: probability.
* p < 0.05.
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Figure  2  Bar diagram indicating the mean ±  SD values of zinc in PCa
and BPH controls. Line and asterisks indicate statistically significant
difference (**p < 0.05).
Table  3  Comparison of zinc and cadmium level in PCa between
different levels of Gleason score.
Cadmium
(g/L)
N, Mean,
median ± SD
Zinc (g/L)
Mean,
median ± SD
Gleason score 5 4, 1.78, 2.04 ± 0.78 92.21, 91.09 ± 8.72
Gleason score 6 15, 1.86, 1.89 ± 0.61 96.82, 92.22 ± 10.51
Gleason score 7 45, 2.97, 2.89 ± 0.95 87.61, 86.66 ± 7.42
Gleason score 8 15, 4.28, 4.55± 0.96 79.8, 78.56 ± 6.25
Gleason score 9 23, 4.98, 5.22 ± 0.91 74.68, 73 ± 6
* *
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* p < 0.05.
 and 7) compare to high risk patients (Gleason score: 8 and 9)Please cite this article in press as: Abhishek A, et al. To study the relatio
Indian patients suffering from prostate cancer: A case control study. A
hile high mean value of Zn was seen in low risk patients and vice
ersa (Table 3). Cd level positively correlated with Gleason score
r: 0.64) and Zn level negatively correlated with Gleason score (r:
I
C
w
Table  4  Comparison of mtDNA copy number with PSA and Gleason sc
Variables PCa
Number (%),
mtDNA copy
number; median
(range)
Serum PSA
<4 5; 14,208 (3331–24,214) 
>4–10 20; 13,250 (2015–34,247)
>10–20 39; 20,487 (1968–31,353) 
>20 36; 16,781 (3471–29,712) 
Gleason score
5 4; 3471 (1968–7895)
6 15; 11,247 (3331–14,987)
7 45; 15,370 (9436–24,681)
8 15; 25,658 (21,747–31,353)
9 21; 26,733 (20,487–34,247) 
p: probability.
* p < 0.05.igure  3  Distribution of mtDNA copy number in PCa and BPH
atients.
0.68) (p  < 0.05). Comparison amongst metals (Cd and Zn) and
ifferent Gleason scores are shown in Table 3.
or the study of distribution pattern of mtDNA, we [compared]
he PCa group with their age matched BPH control. mtDNA
opy number/L in BPH group [range (fold difference)] was
0,178–33,224 (3.9) whereas in PCa group mtDNA was 968–39,245
17.4); this difference was statistically significant (p: 0.036) (Fig. 3).
here was no correlation between mtDNA copy number and serum
SA in PCa patients and their age match BPH control (F: 1.874;
: 0.14; p: 0.139) (Table 4). PCa Patients with higher [Gleason]
core (8–9) were more likely to have higher mtDNA copy number
han those with lower [Gleason] score (5–7) (F: 81.87; r: 0.849; p:
.0001) (Table 3). Patients with a Gleason score of 4 + 3 (7) had
igher mtDNA copy number compared to those with lower score
3 + 4: 7) (Fig. 4). Finally, correlation between mtDNA, Cd, and Zn
evels are documented in Fig. 5.
iscussionnship between cadmium, zinc and mtDNA copy number in North
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2016.05.011
n this study, 88% PCa and 59% BPH control patients were farmers.
admium was detected in almost all samples and their concentration
as significantly higher in PCa compare to BPH control group. Cd
ore.
BPH Control
Number (%),
mtDNA copy
number; median
(range)
78; 17,596 (10,178–28,237)
12; 17,658 (10,354–29,342)
7; 19,925 (14,736–23,237)
2; 14,883 (12,244–17,522) p: 0.13
p: 0.0001*
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lFigure  4  Distribution pattern of mtDNA at different Gleason score
in PCa patients (A); Distribution of mtDNA in Gleason score 7 (B).
positively and Zn negatively correlated with [Gleason] score. The
high level of Cd might be due to the habit of chewing betel quid andPlease cite this article in press as: Abhishek A, et al. To study the relatio
Indian patients suffering from prostate cancer: A case control study. A
smoking homemade tobacco leaf (Biri) which is a major source of
Cd exposure [10]. This unfiltered tobacco chewing is an endemic
habit especially in northern part of India.
Figure  5  Correlation of mtDNA against cadmium and zinc. r: corre-
lation; p: probability.
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reviously, it was though that in India occurrence of PCa is far
ess compared to the western world. As a result of rural to urban
igration, changing life style, increasing awareness regarding PCa,
etter access to medical facility; more and more cases of PCa are
eing discovered. Jain et al. [11] reported that PCa is the second
ost frequently diagnosed cancer in major cities of India. Almost
ll regions of India are equally affected by PCa. The incidence rate
after age adjustment) of PCa in big cities of India is 10.66/100,000
12] which is higher when compared to northern Africa (8.1) and
outh-east Asia (8.3) but is still lower than United State (85.6) and
ther countries of Europe (Eastern zone: 29.1 and Southern zone:
0.0) [13,14]. The incidence rate of PCa in India is constantly and
apidly increasing. It has been projected that the number of patients
uffering from PCa will double by 2020 [11].
inc is very important for the structural integrity of prostate and
igh zinc levels are characteristic of healthy prostate cell. Zinc
nfluences various molecular repair mechanisms of mitochondria
3] and is involved in the development and normal functioning of
he immune system [15]. Cd toxicity has been closely related to Zn
omeostasis. Once inside the cells, cadmium displaces zinc from
roteins and enzymes where zinc has a sulfur-dominated coordina-
ion sphere [16]. Higher concentration of Cd is capable of inhibiting
NA repair and leading to genomic instability, which may be asso-
iated with various types of malignancy [17]. The deleterious effects
f Cd are associated with either acute exposure to high levels of the
lement or chronic exposure to low level of metal. In our study,
o correlation was found between metals (Cd and Zn) and serum
SA in PCa as well as BPH control group. This study suggests
hat rise of Cd level and depletion is of zinc level correlates with
ncreasing Gleason score and is more pronounced with aggressive
isease. Our result corroborate with Cortesi et al. [18] who found
ignificant zinc depletion with increasing Gleason grade. Evidence
uggests that mitochondrial integrity is affected by Cd and zinc
evel.
he association between mtDNA copy number variation and malig-
ancy is still subject of debate. Both an increase and decrease in
tDNA copy number have been associated with an increased risk for
umorigenesis. In genomic DNA extracted from blood, an elevated
opy number has been observed in patients with various cancers. A
rospective study of renal cancer revealed that high mtDNA copy
umber in blood was allied with increased future risk of renal cell
arcinoma [19]. On other hand, decrease in mtDNA copy number
as found in patients with stomach cancer [20].
 precise mechanism for increase in the mtDNA copy number in
lood has not been fully understood. Possibly, increased mtDNA
opy number indicates the increased levels of oxidative damage
hat has been associated with possible cause of different type of
alignancies [21]; it may reflect indirect evidence of carcinogenesis
ather than direct cause [9]. Moreover, low mtDNA copy num-
er in cell can be caused by mitochondrial DNA polymerase 
POLG1) mutation, resulting in tumor initiation and progression
22].
his study revealed that mtDNA copy number is more scattered in
Ca patients compare to controls and the difference was statisticallynship between cadmium, zinc and mtDNA copy number in North
fr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2016.05.011
ignificant. This significance indicates that increase in mtDNA copy
umber in PCa as compare to BPH control. Our results support
revious tissue-based study which showed that the average mtDNA
ontent increased in prostate cancer tissue as compared to benign
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rostatic tissue [9]. Although we compared blood mtDNA copy
umber with two indices of PCa (Serum PSA and Gleason score).
tDNA copy number had no correlation with Serum PSA in PCa
atients. Gleason score is the most important pathological finding
n PCa and main indicator of tumor burden. When we compared
tDNA copy number with different Gleason scores (6–9), a positive
orrelation was found. PCa patients with higher [Gleason] score
ere more likely to have higher mtDNA copy number than their
ith lower [Gleason] score. In prostate cancer, [Gleason] score 7 was
plit into two category i.e. 4 + 3 and 3 + 4. The increase of [Gleason]
core is directly correlated with tumor aggressiveness. Patients with
 [Gleason] score of 4 + 3 (7) tended to have slightly but significantly
igher mtDNA copy number compare to their lower score (3 + 4: 7)
Fig. 4B). Zhou et al. [23] found significant higher blood mtDNA
n advanced stage of PCa as compare to lower stages.
here are few limitations in our study. As with any prospective case
ontrol biomarker study, our study does not allow us to determine
hether mtDNA copy numbers found in PCa patients was the cause
r the result of cancer onset on progression. Moreover, relatively
mall sample size in this study limited our statistical capacity to
etect interactions between metals and mtDNA copy number and
ther major risk factors. Large prospective studies (with a larger
ample size) may confirm our findings.
onclusion
his result suggests that an increased variation of cadmium level
orrelates with increasing [Gleason] score and zinc level negatively
orrelates with increasing [Gleason] score. The Distribution vari-
nce pattern of mtDNA copy number also correlates with [Gleason]
core in PCa patients compare to BPH control.
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